ArticleClinical and experimental immunology2004
Intranasal bacille Calmette-Guerin (BCG) vaccine dosage needs balancing between protection and lung pathology.
Article in Clinical and experimental immunology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Mucosal BCG Vaccination and Immune Layering: Route-Dependent Programming of Immunity at the Respiratory Interface.Vaccines · 2026Review
- A vaccine targeting lung resident-memory CD4NPJ vaccines · 2025Article
- Repurposing mucosal delivery devices for live attenuated tuberculosis vaccines.Frontiers in immunology · 2023Article
- Increased Heme Oxygenase 1 Expression upon a Primary Exposure to the Respiratory Syncytial Virus and a SecondaryAntioxidants (Basel, Switzerland) · 2022Article
- Airway delivery of both a BCG prime and adenoviral boost drives CD4 and CD8 T cells into the lung tissue parenchyma.Scientific reports · 2020Article
- The Humoral Immune Response to BCG Vaccination.Frontiers in immunology · 2019Review
- Sendai Virus Mucosal Vaccination Establishes Lung-Resident Memory CD8 T Cell Immunity and Boosts BCG-Primed Protection against TB in Mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- Quantity and Quality of Inhaled Dose Predicts Immunopathology in Tuberculosis.Frontiers in immunology · 2015Review
- Evolution of M. bovis BCG Vaccine: Is Niacin Production Still a Valid Biomarker?Tuberculosis research and treatment · 2015Review
- The in vivo environment accelerates generation of resuscitation-promoting factor-dependent mycobacteria.American journal of respiratory and critical care medicine · 2014Article
- Antimicrobial treatment improves mycobacterial survival in nonpermissive growth conditions.Antimicrobial agents and chemotherapy · 2014Article
- Pulmonary Mycobacterium bovis BCG vaccination confers dose-dependent superior protection compared to that of subcutaneous vaccination.Clinical and vaccine immunology : CVI · 2014Article
- Article
- Cellular immune responses to nine Mycobacterium tuberculosis vaccine candidates following intranasal vaccination.PloS one · 2011Article
- Reducing the activity and secretion of microbial antioxidants enhances the immunogenicity of BCG.PloS one · 2009Article
- Development of a guinea pig immune response-related microarray and its use to define the host response following Mycobacterium bovis BCG vaccination.Infection and immunity · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intranasal vaccination may offer practical benefits and better protection against respiratory infections, including tuberculosis. In this paper, we investigated the persistence of the Mycobacterium bovis-strain bacille Calmette-Guerin (BCG) Pasteur, lung granuloma formation and protection against pathogenic tuberculous challenge in mice. A pronounced BCG dose-dependent granulomatous infiltration of the lungs was observed following intranasal, but not after subcutaneous, vaccination. Corresponding doses of BCG, over a 100-fold range, imparted similar protection against H37Rv challenge when comparing the intranasal and subcutaneous vaccination routes. Interestingly, a BCG dose-dependent reduction of the H37Rv challenge infection was observed in the lungs, but not in the spleens, following both intranasal and subcutaneous vaccination. In the light of the observed concurrence between the extent of granuloma formation and the level of protection of the lungs, we conclude that intranasal vaccination leading to best protective efficacy needs to be balanced with an acceptable safety margin avoiding undue pathology in the lungs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.